Edition:
United States

Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

14.40USD
22 Sep 2017
Change (% chg)

$1.35 (+10.34%)
Prev Close
$13.05
Open
$13.10
Day's High
$14.40
Day's Low
$13.10
Volume
228,935
Avg. Vol
78,653
52-wk High
$16.45
52-wk Low
$7.50

Chart for

About

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008,... (more)

Overall

Beta: 1.65
Market Cap(Mil.): $357.71
Shares Outstanding(Mil.): 24.84
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.89 16.34
EPS (TTM): -- -- --
ROI: -- 3.08 14.66
ROE: -- 4.82 14.00

BRIEF-Zogenix Q2 loss per share $0.93

* Zogenix provides corporate update and reports second quarter 2017 financial results

Aug 08 2017

BRIEF-Zogenix and Durect Corp enter into termination agreement

* Says on august 1, co and Durect Corporation entered into a termination agreement - sec filing

Aug 03 2017

BRIEF-Zogenix Q1 loss per share $0.86

* Zogenix provides corporate update and reports first quarter 2017 financial results

May 04 2017

BRIEF-Zogenix completes enrollment in first ZX008 Phase 3 clinical trial in Dravet syndrome

* Zogenix completes enrollment in first zx008 phase 3 clinical trial in dravet syndrome

Apr 27 2017

Earnings vs. Estimates